These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 24597388)
21. No change in scope for extension of patent term for pharmaceutical substances under Australian law: an update. Lyons M; Stark A Pharm Pat Anal; 2017 Nov; 6(6):251-254. PubMed ID: 29022759 [No Abstract] [Full Text] [Related]
22. Compulsory licensing of patents in India. Chaudhry R Pharm Pat Anal; 2016 Sep; 5(6):401-406. PubMed ID: 27805847 [TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical patent challenges--time for reassessment? Glass G Nat Rev Drug Discov; 2004 Dec; 3(12):1057-62. PubMed ID: 15573104 [TBL] [Abstract][Full Text] [Related]
24. Patents to "treat me", no patents to "test me": an analysis of the 2009 Senate inquiry into gene patents. Triffett D J Law Med; 2010 May; 17(5):800-6. PubMed ID: 20552942 [TBL] [Abstract][Full Text] [Related]
25. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II. Leary TB J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411 [TBL] [Abstract][Full Text] [Related]
26. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
27. The consequences of 'double examination' for pharmaceutical patent applications in Brazil. Salerno G Pharm Pat Anal; 2017 Mar; 6(2):49-51. PubMed ID: 28274178 [No Abstract] [Full Text] [Related]
28. First-to-invent versus first-to-file: impact of the AIA. Rachinsky T; Sullivan C; Ghosh S; Resnick DS; Burton C; Armstrong M; Hanish JP; Sklan A Pharm Pat Anal; 2014 Jul; 3(4):353-9. PubMed ID: 25291309 [TBL] [Abstract][Full Text] [Related]
29. Expedited pharma patenting in Brazil. Moreira P Pharm Pat Anal; 2019 Mar; 8(2):51-59. PubMed ID: 30887881 [TBL] [Abstract][Full Text] [Related]
30. Patent protection in Europe of pharmaceuticals found to have a further medical indication. Cockbain J Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708 [No Abstract] [Full Text] [Related]
31. EU court gets tough on patent extensions for combo products. Waters H Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647 [No Abstract] [Full Text] [Related]
32. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA. Vines T; Crow K; Faunce T J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847 [TBL] [Abstract][Full Text] [Related]
33. [Drug patents and other ways to protect pharmaceutical research]. Ohana P; Tardieu S; Blin O; Tassy S; Sambuc R Therapie; 2004; 59(2):253-7. PubMed ID: 15359623 [TBL] [Abstract][Full Text] [Related]
34. Patent watch: Progress in three key patent disputes in 2009. Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395 [No Abstract] [Full Text] [Related]
35. An overview of pharmaceutical patent litigation in China. Carver T Pharm Pat Anal; 2016; 5(2):75-7. PubMed ID: 26891143 [No Abstract] [Full Text] [Related]
36. Amendment to UK Patent Act provides further exception to patent infringement. Sklan A Pharm Pat Anal; 2014 Jul; 3(4):349. PubMed ID: 25291308 [No Abstract] [Full Text] [Related]
37. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles? Hollis A Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123 [No Abstract] [Full Text] [Related]
38. Patenting pharmaceuticals in China. Han W; Luo J Pharm Pat Anal; 2016 Jul; 5(4):249-59. PubMed ID: 27338759 [TBL] [Abstract][Full Text] [Related]
39. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association. Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229 [TBL] [Abstract][Full Text] [Related]